I used to be more aggravated by ...... delays/snail's pace enrollment /etc. in the Tigris Trial.
While still aggravated, now I am
less so.
Why ?
With each passing day the
underlying value * of the Company should be going up (albiet it is not very well reflected in the SP**)
How is the *value going up over time?:
- Exceeding expectations in the Tigris portion increases the overall mortality Benefit (MB) of the final Euphrates/Tigris Trial result. Averaging increasingly better results of Tigris (e.g potentially > 20%?) with the 10% MB under Euphrates, yeilds a higher overall MB..and this fact can be used to justify a much higher price per column, upon ultimate FDA approval...and that means more revenues..and that means a higher asking price.
- Enables Eden Study to expand the usage label (i.e. ultimately wider use of PMX) which means more reveunue to the ultimpte buyer of NA Rights...and therefore it justifies a higher asking price.
- More RWE coming to the fore (e.g PMX for Covid ). If more Studies are completed that shown PMX to be (for example) a treatement for severe Covid...then that means more revenues....and ultimately a higher asking price.
- Breakthrough Device Designation this past summer. Probablity of ultimate Approval raised and time to market shortened.
* * why is the underlying and increasing value not better reflected in the current SP ? The Company has not invited/enticed newbie investors. The ultimate value of PMX Dialco and the EAA is murky (at best) to unguided investors...unless they do a great deal of DD (which only a few here have bothered to do). Newbie investors prefer to rely on a very transparent and independent analysts with a large following (the more Analysts, and the more clients of the Analysts, the better). Of course a US Listing would help to expand the demand side, but I don't see how that is in the cards (or it would have happened by now)
Conclusions, cheap shares for another X months (weeks?)....
MM